FIB-4 Score Calculation and Interpretation

Introduction to FIB-4

The FIB-4 score is calculated using the formula: Age (years) × AST (IU/L) / [Platelet count (×10⁹/L) × √ALT (IU/L)] [1, 2, 3]

To calculate FIB-4, you need four specific values: Age in years, AST (aspartate aminotransferase) in IU/L, ALT (alanine aminotransferase) in IU/L, and Platelet count in ×10⁹/L 1, 2, 3

FIB-4 <1.3: Low probability of advanced fibrosis, with a negative predictive value of approximately 90% for advanced fibrosis 1, 2, 3
FIB-4 1.3-2.67: Indeterminate range requiring additional testing such as elastography or Enhanced Liver Fibrosis (ELF) testing 1, 2, 3
FIB-4 >2.67: High probability of advanced fibrosis, with a positive predictive value of approximately 65% for advanced fibrosis 1, 3

FIB-4 has an AUROC of approximately 0.77-0.86 for detecting advanced fibrosis, depending on the population studied 2
The test performs best at ruling out advanced fibrosis (high negative predictive value) rather than confirming it 2, 3

FIB-4 has limited accuracy in the intermediate range (1.3-2.67), where approximately 30-40% of patients fall, necessitating additional testing 2, 3
Age significantly affects FIB-4 values: The score naturally increases with age, leading to higher false-positive rates in elderly patients and potential false-negatives in younger patients 2
Diabetes and metabolic syndrome may reduce diagnostic accuracy in NAFLD populations 2

When FIB-4 is <1.3 (or <2.0 if age ≥65): Advanced fibrosis is unlikely, repeat testing every 1-3 years in at-risk populations 2, 3
When FIB-4 is 1.3-2.67: Proceed to liver elastography (FibroScan, VCTE) as second-line test, or implement 1-year lifestyle intervention and retest 2, 3
When FIB-4 is >2.67: High probability of advanced fibrosis, refer to hepatology for comprehensive evaluation, and consider elastography or liver biopsy for confirmation and staging 1, 2, 3

The American Association for the Study of Liver Diseases recommends using the FIB-4 index to exclude advanced fibrosis in patients with chronic hepatitis C, with a FIB-4 <1.45 indicating a low probability of advanced fibrosis 4

For patients with non-alcoholic fatty liver disease (NAFLD), a FIB-4 >2.67 indicates a high probability of advanced fibrosis, with a positive predictive value of approximately 65% 4
For patients with chronic hepatitis C, a FIB-4 >3.25 indicates a high probability of advanced fibrosis, with a specificity of 85-90% 4

The FIB‑4 index is calculated as Age (years) × AST (U/L) ÷ [Platelet count (×10⁹/L) × √ALT (U/L)]【5】.

In patients younger than 65 years, a FIB‑4 < 1.3 reliably excludes advanced fibrosis (stage F3‑F4) with a negative predictive value > 90 %【5】【6】.
The area under the receiver‑operating characteristic curve (AUROC) for FIB‑4 in detecting advanced fibrosis ranges from 0.77 to 0.86, varying with the studied population【5】【6】.
For individuals aged 35‑64 years, the FIB‑4 test performs optimally, providing high reliability for this age group【5】【6】.

Monitoring frequency: Repeat FIB‑4 testing every 2–3 years while encouraging lifestyle changes that address metabolic risk factors【5】.
Weight management: Aim for a 7‑10 % body‑weight reduction through caloric restriction and a diet low in saturated fats when metabolic‑syndrome features are present【5】.
Follow‑up intensity: Patients with type 2 diabetes or multiple metabolic‑syndrome components should be reassessed annually; otherwise, a 2‑3‑year interval is sufficient【5】.

Screening for MASLD: Evaluate for metabolic‑dysfunction‑associated steatotic liver disease by checking for obesity, diabetes, dyslipidemia, and hypertension【5】.
A low FIB‑4 score indicates that mild ALT elevation has not yet progressed to significant fibrosis【6】.
Age‑specific cut‑offs: For a 39‑year‑old, the low‑risk threshold is < 1.3; the higher threshold < 2.0 applies only to patients ≥ 65 years【5】【6】.